Top 10 Heal Care Stocks To Own Right Now

Job fair: Some 1.3 million unemployed workers will lose federal benefits by Dec. 28, but the White House wants Congress to extend help another year.

WASHINGTON (CNNMoney) President Obama's newest priority is pushing Congress to extend federal unemployment benefits by another year, and Republicans say they're willing to consider the idea.

Benefits for 1.3 million workers will expire Dec. 28 if Congress fails to extend a recession-era program by the end of this month.

The White House Council of Economic Advisers and Department of Labor issued a joint report touting how jobless benefits buoy the economy, while keeping 2.5 million workers out of poverty each year.

Allowing unemployment benefits to expire "would be harmful to millions of workers and their families," according to the report.

Top 5 Integrated Utility Companies To Watch In Right Now: Powerdyne International Inc (PWDY)

Powerdyne International, Inc., formerly Greenmark Acquisition Corporation, incorporated on September 13, 2006, is a development-stage company. The Company focuses on manufacturing, installing, maintaining, owning and operating portable electrical power generation equipment (gensets).

The Company's initial product is the PDIGenset, which is a self contained generator that is powered by a modified radial air cooled engine to drive a minimum of a 1-megawatt generator. The entire unit, which runs on natural gas or propane, is compact, lightweight and clean burning. The Company also focuses on the process of building its first prototype of the PDIGenset. As of December 31, 2010, the Company had not generated any revenues.

The Company competes with Caterpillar Corporation, Cummings, Morse Diesel, Kohler, Volvo and Detroit Diesel.

Advisors' Opinion:

• [By Peter Graham]

  On Friday, small cap stocks EHouse Global (OTCBB: EHOS), Sanwire Corporation (OTCMKTS: SNWR) and Powerdyne International Inc (OTCBB: PWDY) sank 37.38%, 29.47% and 23.23%, respectively, despite some evidence of paid stock promotions or investor relation campaigns. Of course, volatility is a given for small cap OTC stocks, but paid stock promotions or investor relations campaigns tend to add to that volatility. With that in mind, what will these three small cap stocks do for investors this holiday trading week? Here is a closer look to help you decide on a trading or investment strategy:

Top 10 Heal Care Stocks To Own Right Now: Autobytel Inc.(ABTL)

Autobytel Inc. operates as an automotive marketing services company in the United States. It assists automotive retail dealers and manufacturers to market and sell new and used vehicles to consumers through its online purchase request referrals, dealer marketing products and services, and online advertising programs and data products. The company provides vehicle purchase request programs, including new vehicle purchase request program, which allows consumers to submit requests for pricing and availability of specific makes and models; used vehicle purchase request program that allows consumers to search for used vehicles according to specific search parameters, such as the price, make, model, mileage, year, and location of the vehicle; and finance purchase request program designed to provide consumers the opportunity to obtain vehicle financing and other services from dealers or finance institutions. Its network of company-owned consumer-facing automotive Websites compris e Autobytel.com, which provide consumers the information and tools to aid them with their automotive purchase decisions and the ability to submit inquiries requesting dealers to contact the consumers for purchasing or leasing vehicles. In addition, the company provides products and services that assist dealers in connecting with in-market consumers and closing vehicle sales. The company, formerly known as Autobytel.com Inc., was founded in 1995 and is headquartered in Irvine, California.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  In trading on Wednesday, cyclical consumer goods & services shares were relative leaders, up on the day by about 0.41 percent. Meanwhile, top gainers in energy sector included Autobytel (NASDAQ: ABTL), with shares up 20.6 percent, and VisionChina Media (NASDAQ: VISN), with shares up 15.5 percent.

Top 10 Heal Care Stocks To Own Right Now: Nikon Corp (NINOY)

NIKON CORPORATION is a Japan-based company mainly engaged in the manufacture and sale of optical products. The Company is active in four business segments. The Precision Apparatus segment offers semiconductor exposure apparatus and liquid crystal (LC) exposure apparatus. The image segment provides digital cameras, film cameras and interchangeable lens. The Instruments segment offers microscopes, measuring machines and semiconductor inspection equipment. The Others segment provides glass materials, telescopes, glasses and survey airplanes.

As of August 19, 2009, the Company held a 92.17% stake in Metis NV. The Company has 65 subsidiaries and 10 associated companies in the country and overseas markets.

Advisors' Opinion:

• [By Dan Carroll]

  Unfortunately, the yen's impact on stocks has blurred the lines on investments. Look no further than down-on-its-luck camera maker Nikon (NASDAQOTH: NINOY  ) . Nikon's shares gained more than 8% over the past week due to the yen's weakness, as the company rakes in more than a quarter of its sales in Europe. Still, the stock's lost more than 43% year to date.

Top 10 Heal Care Stocks To Own Right Now: Fidus Investment Corp (FDUS)

Fidus Investment Corporation, incorporated on February 14, 2011, provides customized mezzanine debt and equity financing solutions to lower middle-market companies. The Company�� investment objective is to provide attractive risk-adjusted returns by generating both current income from its debt investments and capital appreciation from its equity related investments.

The Company seeks to maintain a diversified portfolio of investments in order to help mitigate the potential effects of adverse economic events related to particular companies, regions or industries. The Company�� investment advisor is Fidus Capital, LLC.

Advisors' Opinion:

• [By BDC Buzz]

  Fidus Investment (FDUS) is one of the newer business development companies ("BDCs") but its stock performance has been strong with a steady climb to higher than average multiples. This is most likely due to its higher than average 'total return' of around 16%. Last quarter FDUS grew its net asset value ("NAV") per share more than any of the other 25 BDCs that I follow and announced a special dividend on top of its regular dividends which is currently yielding around 8%. The company announced that it received approval for a second SBIC license giving it access to cheap long-term growth capital to grow the portfolio and dividends. FDUS also reported realized gains in Q3 from exited investments that could provide for some large upcoming special dividends. I believe that investors should look beyond the current lower than average dividend yield and higher than average pricing multiples, and consider the potential total return for FDUS over the coming quarters. I will also address my key concerns for the company and some things to watch for through the end of the year.

Top 10 Heal Care Stocks To Own Right Now: LRR Energy LP (LRE)

LRR Energy, L.P (LRR Energy) is a limited partnership formed by affiliates of Lime Rock Resources to operate, acquire, exploit and develop producing oil and natural gas properties in North America. The Company�� properties are located in the Permian Basin region in West Texas and southeast New Mexico, the Mid-Continent region in Oklahoma and East Texas and the Gulf Coast region in Texas. As of March 31, 2011, the Company�� total estimated proved reserves were approximately 30.3 million barrels of oil equivalent (MMBoe), of which approximately 84% were proved developed reserves. During the year ended December 31, 2010, approximately 55% of its pro forma revenues were from oil and natural gas liquids (NGLs) and approximately 37% of its total estimated proved reserves were oil and NGLs. As of March 31, 2011, the Company operated 93% of its proved reserves. Based on its pro forma average net production of 6,503 barrels of oil equivalent per day (Boe/d) for December 31, 2010, the Company�� total estimated proved reserves as of March 31, 2011 had a reserve-to-production ratio of approximately 12.8 years. In January 2013, the Company acquired oil and natural gas properties in the Mid-Continent region in Oklahoma from its sponsor, Lime Rock Resources. In April 2013, it announced that it closed its acquisition of oil and natural gas properties in the Mid-Continent region in Oklahoma.

The Company�� general partner, LRE GP, LLC, is controlled by Lime Rock Management LP. The Company�� general partner has sole responsibility for conducting its business and for managing its operations. The Company�� properties consist of mature, low-risk onshore oil and natural gas reservoirs with long-lived, predictable production profiles located across three diverse producing regions: the permian basin region in west texas and southeast new mexico, the mid-continent region in oklahoma and east texas, and the gulf coast region in texas. As of March 31, 2011, the Company�� estimated proved developed non-! producing reserves included 192 gross (158 net) recompletion, refracture stimulation and workover projects. In addition, as of March 31, 2011, the Company�� proved undeveloped reserves included 213 gross (140 net) identified drilling locations.

As of March 31, 2011, approximately 55% of the Company�� estimated proved reserves and approximately 44% of its pro forma average daily net production for the three months ended December 31, 2010, were located in the Permian Basin region. Approximately 60% of the Company�� estimated net proved reserves in the Permian Basin region are oil and NGLs. The Permian Basin is one of the oil and natural gas producing basins in the United States, extending over 100,000 square miles in West Texas and southeast New Mexico, and has produced over 24 billion barrels of oil. The Company owns an 83% average working interest across 665 gross (552 net) wells and operates approximately 92% of its properties in the Permian Basin. The Company�� estimated proved reserves for its Permian Basin properties as of March 31, 2011 totaled 16.6 MMBoe and had a standardized measure of $237.7 million, which represented 69% of the total standardized measure for all of its estimated proved reserves.

The Company�� properties in the Red Lake area is an oil-weighted field located in Eddy County, New Mexico. The Red Lake properties have produced approximately 4.9 MMBoe. The primary producing formations are the San Andres and Yeso at a depth of approximately 2,000 to 5,000 feet. The Company operates approximately 99% of its proved reserves in the Red Lake area, including 157 gross (144 net) producing wells in the field with an average working interest of 92%, and own a non-operated working interest in 10 gross (3 net) additional wells in the area with an average working interest of 31%. The Company�� properties in the field contained 9.6 MMBoe of estimated net proved reserves as of March 31, 2011, approximately 86% of which are oil and NGLs, and generated average n! et produc! tion of 1,410 Boe/d for December 31, 2010. These properties represented 32% of its total estimated proved reserves as of March 31, 2011 and 22% of the Company�� pro forma average net production for December 31, 2010. In addition, these properties had a standardized measure of $163.3 million as of March 31, 2011, which represented 48% of the total standardized measure for all of the Company�� estimated proved reserves.

The Company�� properties in the Pecos Slope area is a gas-weighted field located in Eddy, Chaves, Lea and Roosevelt Counties, New Mexico. The Company operates approximately 100% of its proved reserves in the Pecos Slope area, including 434 gross (382 net) producing wells in the field with an average working interest of 88%. The Company�� Willow Lake field is an oil-weighted field located in Eddy County, New Mexico. There are 41 gross (8 net) producing wells in this area with an average non-operated working interest of 19%. The Cowden Ranch area is an oil-weighted field located in Crane County, Texas. The Company operate s100% of its proved reserves in the Cowden Ranch area, including 8 gross (approximately 5 net) producing wells in the field with an average working interest of 71%. The Company�� properties in the Corbin and Vacuum have produced approximately 3.0 MMBoe. The Company operates 100% of its proved reserves in the Corbin and Vacuum areas, including 8 gross (8 net) producing wells with an average working interest of 100%.

As of December 31, 2010, approximately 33% of the Company�� estimated proved reserves and approximately 38% of its pro forma average daily net production for December 31, 2010 were located in the Mid-Continent region. The Company�� Potato Hills Area is an Arkoma Basin natural gas property located in Latimer and Pushmataha Counties in Southeast Oklahoma. The Company�� Reklaw properties have produced approximately 5.6 MMBoe. The Company operates 100% of its proved reserves in the Reklaw area, including 63 gross (61 net) pro! ducing we! lls in the field with an average working interest of 97%. Its properties in the Black Bayou-Doyle Creek area is a natural gas-weighted field located in Angelina, Cherokee and Nacogdoches Counties, Texas, in close proximity to the Reklaw area. The Company�� non-operated interest in 43 gross (approximately 12 net) producing wells in the field with an average non-operated working interest of 26%.

As of March 31, 2011, approximately 12% of the Company�� estimated proved reserves and approximately 18% of its pro forma average daily net production for December 31, 2010 were located in the Gulf Coast region. Approximately 31% of the Company�� estimated net proved reserves in the Gulf Coast region are oil and NGLs. The Company owns an 82% average working interest across 42 gross (35 net) wells and operates 100% of its properties in the Gulf Coast region. The Company�� property New Years Ridge area is a natural gas-weighted field located in DeWitt County, Texas. The Company�� George West-Stratton areas consist of natural gas-weighted fields located in Live Oak and Hidalgo Counties, Texas. The Company�� operates 100% of its proved reserves in the George West-Stratton areas, including 23 gross (17 net) producing wells in the George West-Stratton areas with an average working interest of 73%.

Advisors' Opinion:

• [By Robert Rapier]

  I am going to address LRR Energy LP (NYSE: LRE) and Memorial Production Partners LP (NASDAQ: MEMP) in an upcoming issue of MLP Investing Insider.

  (Follow Robert Rapier on Twitter, LinkedIn, or Facebook.)

Top 10 Heal Care Stocks To Own Right Now: Mellanox Technologies Ltd.(MLNX)

Mellanox Technologies, Ltd., a fabless semiconductor company, engages in the design, development, marketing, and sale of interconnect products primarily in North America, Israel, Europe, and Asia. It offers semiconductor interconnect products that facilitate data transmission between servers, communications infrastructure equipment, and storage systems in enterprise data centers, high-performance computing, and embedded systems. The company provides solutions based on InfiniBand, including host channel adapter, switch and gateway ICs, adapter cards, switch and gateway systems, cables, and software. Its products also support the Ethernet standard. The company provides adapters to server, storage, communications infrastructure, and embedded systems OEMs as ICs or standard card form factors with PCI-X or PCI express interfaces; support server operating systems, including Linux, Windows, AIX, HPUX, Solaris, and VxWorks; and InfiniBand switch ICs to server, storage, communicati ons infrastructure, and embedded systems OEMs to create switching equipment. The company offers its products under the Mellanox, BridgeX, ConnectX, InfiniBlast, InfiniBridge, InfiniHost, InfiniPCI, InfiniRISC, PhyX, InfiniScale, and Virtual Protocol Interconnect trademarks in the United States. It primarily serves enterprise data center, high-performance computing, and embedded end-user markets, as well as embedded systems OEMs. The company sells its products directly, as well as through a network of domestic and international sales representatives, and independent distributors. Mellanox Technologies, Ltd. was incorporated in 1999 and is headquartered in Yokneam, Israel.

Advisors' Opinion:

• [By Luke Jacobi]

  Mellanox Technologies (NASDAQ: MLNX) also closed up, gaining 5.90 percent to $37.97 after the company announced general availability of MetroX solutions.

• [By Jake L'Ecuyer]

  Mellanox Technologies (NASDAQ: MLNX) was also up, gaining 7.31 percent to $38.48 after the company announced general availability of MetroX solutions.

• [By Alex Planes]

  What: Shares of Mellanox Technologies (NASDAQ: MLNX  ) lost nearly 13% of their value today despite beating expectations last night. Analysts at two investment firms are not at all convinced that last night's good news will translate into long-term strength.

• [By Jake L'Ecuyer]

  Top losers in the sector included CommVault Systems (NASDAQ: CVLT), off 28 percent, and Mellanox Technologies (NASDAQ: MLNX), down 13 percent.

  Top Headline
  Ford Motor Co (NYSE: F) reported a drop in its first-quarter profit. Ford's quarterly profit slipped to $989 million, or $0.24 per share, versus a year-ago profit of $1.61 billion, or $0.40 per share. Its revenue rose to $35.9 billion versus $35.6 billion. However, analysts were projecting earnings of $0.31 per share on revenue of $34.54 billion.

Top 10 Heal Care Stocks To Own Right Now: Cancer Genetics Inc (CGIX)

Cancer Genetics, Inc. (CGI), incorporated on April 8, 1999, is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.

The Company is in the final stages of validating MatBATM-SLL for risk stratification in small lymphocytic lymphoma (SLL), a subset of CLL that presents as a mass, with Memorial Sloan-Kettering Cancer Center and Long Island Jewish / North Shore Hospital. The Company is also internally clinically validating the MatBATM microarray in a variety of additional lymphoma subtypes, including mantle-cell lymphoma (MCL), follicular lymphoma (FL), and diffuses large B cell lymphoma (DLBCL). Its MatBATM array has been designed to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms.

CGI is also developing microarray tests for the diagnosis, prognosis and theranosis of a range of urogenital cancers. These include the UroGenRA microarray for kidney, prostate and bladder cancers and the UGenRA microarray for endometrial (lining of the uterus), ovarian and cervical cancers. UroGenRA detects genomic changes in over 100 r! egions of the human genome with potential diagnostic and/or prognostic value in one or more of these types of cancer. It has initiated clinical validation for UroGenRA targeting kidney and prostate cancers in collaboration with Memorial Sloan-Kettering Cancer Center. Its UGenRA microarray has been designed as a platform to detect genomic changes occurring in 83 regions of the human genome that have been linked to endometrial, ovarian and cervical cancers In addition, it develop and manufacture a portfolio of fluorescence in situ hybridization (FISH) based DNA probes focused on blood-based and solid cancers that it sell outside the United States. The Company laboratory services include: Oncology Testing Services, which are based on its microarray tests and are available only in its clinical laboratory; Esoteric Oncology Testing Services, which it offers a suite of esoteric oncology testing services for hematological, urogenital and HPV-associated cancers, and Clinical Trial Services, which also utilize its clinical laboratory to provide clinical trial services to biopharmaceutical companies and clinical research organizations.

Hematological Cancer Arrays: MatBA-CLL/SLL, Other Mat-BA and LeukA

MatBA is an oligonucleotide-based microarray the Company developed for the analysis of genomic alterations in mature B-cell neoplasms to determine prognosis and theranosis. MatBA incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display clinical, pathologic and genetic complexity. Importantly, the clinical course of the six main subtypes of these neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL).

MatBA is designed to detect genomic copy number chan! ges in ma! ture B-cell neoplasms. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the cancer specimen (array-CGH). Array-CGH utilizes minimal biopsy material and uses DNA as the analyte (the component whose properties are being measured). MatBA was custom-designed to represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA simultaneously permits the detection of genomic gains and losses at multiple locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. For each subtype of B-cell neoplasm, cohorts of specimens with full clinical annotation are evaluated using MatBA to identify associations between single and weighted combinations of genomic gains/losses and clinically relevant endpoints.

The Company offers the application of MatBA for prognostication in one subtype of mature B-cell neoplasm, CLL, where about half of patients experience indolent disease, or slow progression, and the remaining half, a relatively aggressive progression. MatBA-CLL provides genetic-based information to guide clinical management of this disease. In January 2012, MatBA-SLL was approved under CLIA and accordingly may now be offered as an LDT by its laboratory. In January 2013, this assay received approval by CLIA and New-York State for clinical use, and accordingly may now be offered as an LDT by our reference laboratory.

During the year ended December 31, 2012, the Company had similar development of MatBA as a prognostic tool in two of the other main subtypes of mature B-cell lymphomas, namely DLBCL and FL. FL is characterized by a slow progression that in up to approximately 60% of cases transforms to DLBCL, an aggressive lymphoma. Prognostic and theranostic biomarkers of therapeutic options are req! uired for! these diseases.

Urogenital cancer arrays: UroGenRA, UGenRA

The UroGenRA microarray provides diagnostic and prognostic analysis for kidney, bladder and prostate cancer. Its initial launch, UroGenRA-Kidney targets kidney cancer. It also develops extensions of UroGenRA for bladder and prostate cancers. UGenRA provide diagnostic, prognostic and theranostic information for the primary gynecological cancers, cervical, ovarian and endometrial. UroGenRA is a CGH-based array which serves as a platform for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It represents 101 regions of the human genome potentially with diagnostic, prognostic and/or theranostic value in one or more of these types of cancers. UroGenRA-Kidney For kidney cancer, UroGenRA is specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, chromophobe and oncocytoma), which is critical to patient management and treatment protocols.

UroGenRA-Prostate for prostate cancer, UroGenRA use prostate core/needle biopsy to assess genomic variability of the cancer and help in the identification of biomarkers for assessment of the risk of recurrence, to assess treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. UroGenRA-Prostate is in the commercial development stage. UroGenRA-Bladder is a diagnosed bladder cancers are defined by the fact or extent of invasion of the muscle. UroGenRA-Bladder is in the clinical development stage.

UGenRA for Endometrial, Ovarian and Cervical Cancers

UGenRA is designed as a platform to detect gains and losses of genomic material in 83 regions of the chromosome associated with responses to particular therapies in patients with endometrial, ovarian and cervical. UGenRA-Endometrial Endometrial cancer is common cancer in women in the United States. In this disease, endometrial hyperplasia is a precursor lesion of endometr! ioid endo! metrial carcinoma (EEC). UGenRA Endometrial is in the clinical development stage.

UGenRA-Ovarian is cases of ovarian cancer. UGenRA Ovarian is in the clinical development stage. As of December 31, 2012, UGenRA-Cervical was approximately 11,270 cases of cervical cancer diagnosed and approximately 4,290 deaths from cervical cancer in the United States. UGenRA Cervical is in the clinical development stage.

Advisors' Opinion:

• [By RedChip]

  In an amended S-1 filed with the SEC this morning, Cancer Genetics, Inc. (NASDAQ: CGIX) added two new firms to its offering syndicate and upped its capital raise 25% to $50 million. With the underwriters��overallotment, the total raise is now forecasted to reach as much as $57.5 million.